Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 1.13% | 163.56 | 0.7% | $1160.35m | |
| PFE | Pfizer Inc. | 0.19% | 36.55 | 0.9% | $1138.06m | |
| LLY | Eli Lilly & Co. | 1.95% | 206.30 | 1.1% | $934.48m | |
| ABBV | AbbVie, Inc. | -0.34% | 110.88 | 1.9% | $732.28m | |
| BMY | Bristol-Myers Squibb Co. | 0.61% | 64.57 | 1.0% | $679.31m | |
| MRK | Merck & Co., Inc. | -0.26% | 80.97 | 0.7% | $677.96m | |
| AZN | AstraZeneca Plc | 1.33% | 53.25 | 1.2% | $669.74m | |
| ARCT | Arcturus Therapeutics Holdings, Inc. | 6.16% | 67.70 | 0.0% | $229.98m | |
| GRTS | Gritstone Oncology, Inc. | 6.11% | 27.11 | 0.0% | $211.05m | |
| VTRS | Viatris, Inc. | 0.69% | 17.43 | 0.0% | $193.56m | |
| RPRX | Royalty Pharma Plc | 1.47% | 51.16 | 0.2% | $174.27m | |
| NVS | Novartis AG | 0.06% | 96.94 | 0.2% | $174.04m | |
| GSK | GlaxoSmithKline Plc | 1.54% | 38.36 | 0.2% | $154.42m | |
| SNY | Sanofi | 0.10% | 49.69 | 0.2% | $134.98m | |
| RGEN | Repligen Corp. | 1.11% | 219.32 | 6.9% | $78.39m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.